Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) CFO Pamela Ann Connealy acquired 88,850 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $174,146.00. Following the completion of the purchase, the chief financial officer now owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Pyxis Oncology Price Performance
Shares of Pyxis Oncology stock opened at $2.01 on Friday. The firm has a market cap of $119.53 million, a price-to-earnings ratio of -1.95 and a beta of 1.27. The stock’s 50-day moving average is $3.46 and its 200-day moving average is $3.53. Pyxis Oncology, Inc. has a one year low of $1.56 and a one year high of $6.85.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Royal Bank of Canada lifted their price objective on Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, November 21st. Stephens began coverage on Pyxis Oncology in a report on Friday, November 8th. They set an “overweight” rating and a $13.00 target price on the stock. Stifel Nicolaus began coverage on Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 target price on the stock. Finally, William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.
Institutional Trading of Pyxis Oncology
A number of institutional investors have recently modified their holdings of the company. Barclays PLC lifted its holdings in shares of Pyxis Oncology by 275.0% in the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock valued at $235,000 after purchasing an additional 46,997 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Pyxis Oncology by 5.5% in the third quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock valued at $3,982,000 after purchasing an additional 57,016 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Pyxis Oncology in the third quarter valued at about $107,000. XTX Topco Ltd increased its position in shares of Pyxis Oncology by 133.6% in the third quarter. XTX Topco Ltd now owns 84,771 shares of the company’s stock valued at $311,000 after acquiring an additional 48,481 shares during the last quarter. Finally, Jane Street Group LLC increased its position in shares of Pyxis Oncology by 40.8% in the third quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after acquiring an additional 14,349 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- Stock Sentiment Analysis: How it Works
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Penny Stocks Ready to Break Out in 2025
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.